At Alere, we aim to improve clinical outcomes, reduce healthcare costs and deliver earnings growth to our investors. We strive to build open relationships with our shareholders and prospective investors, and we manage these relationships in accordance with company policies and relevant securities law.
A global leader in rapid point-of-care diagnostics, our products, as well as our new product development efforts, focus on infectious disease, cardiometabolic disease and toxicology. Being a leading developer of innovative diagnostic and monitoring devices allows us to improve care and lower healthcare costs for both providers and patients.
Thank you for your interest in Alere. Find out more about Our Strategy